Cancer detection firm Grail announced sizable workforce cuts on Tuesday in a bid to save cash and concentrate resources on developing a blood-based test to
SAN DIEGO — The unwinding of Illumina’s ill-fated acquisition of Grail earlier this year left investors and the genomics community with a pressing question: What
Acelyrin, a California biotech focused on immunology and inflammatory disease, announced Tuesday that its experimental drug for a common skin disorder succeeded in a late-stage
VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health
NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative
Children born with a damaged gene needed for healthy brain development, SYNGAP1, experience seizures, sensory processing disorders, difficulty speaking, intellectual disability, and autism-like behaviors.
Depression is common among people with likely incurable cancer – understandably so. But studies have shown that it can be treated, and if the goal
The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $165 million for new patient-centered comparative clinical effectiveness research
Ann & Robert H. Lurie Children’s Hospital of Chicago, in partnership with University of Utah Health, has been approved for $12 million in research funding